Tony Clark denounces MLB salary cap talk as 'institutional collusion' during All-Star break
MLB Players Association
executive director
Tony Clark
reaffirmed the union's firm opposition to a salary cap, warning it would be a regressive step for the sport. Speaking ahead of the All-Star Game, Clark argued that MLB's reported push for a cap - led by commissioner
Rob Manfred
- is aimed at profit protection rather than the game's growth.
Manfred has expressed interest in introducing a salary cap in the next
collective bargaining agreement
, citing the need for improved competitive balance. However, Clark dismissed that rationale, saying the league is thriving with rising attendance and viewership.
"You would think there would be an opportunity to talk about how to build rather than how to go backward," Clark said. "What the interests are that they have is taking the game backward."
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
This Could Be the Best Time to Trade Gold in 5 Years
IC Markets
Learn More
Undo
Clark also characterized the cap proposal as '
institutional collusion
' suggesting it's an attempt to suppress player salaries under the guise of economic reform.
"A cap is not about a partnership. A cap is not about growing the game," Clark said. "A cap is about franchise values and profits."
Live Events
While open to improving the current system, Clark emphasized that the union has already made proposals to refine the existing structure and will continue to do so without conceding to a cap model.
The current collective bargaining agreement expires on December 1, 2026. Without a new deal,
MLB
could face a lockout that threatens the 2027 season-a looming labor standoff that now has salary cap tensions at its core.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
16 minutes ago
- Time of India
Tech Mahindra Q1 Results: Cons PAT surges 34% YoY to Rs 1,141 crore, misses Street estimates
Tech Mahindra on Wednesday reported a 34% growth in its Q1FY26 consolidated net profit at Rs 1,141 crore versus Rs 851 crore in the year ago period. The profit is attributable to the owners of the company and is below Street's estimates Rs 1,211 crore. The company's revenue for the reported quarter rose 2.7% to Rs 13,351 crore versus Rs 13,005 crore in the year ago period, but marginally missed Street's estimates of Rs 13,374 crore. Explore courses from Top Institutes in Select a Course Category Finance Management Product Management MBA Data Science Public Policy Data Analytics PGDM Healthcare Artificial Intelligence Cybersecurity Digital Marketing Others others Project Management CXO healthcare Degree Leadership Data Science Design Thinking MCA Technology Operations Management Skills you'll gain: Duration: 9 Months IIM Calcutta SEPO - IIMC CFO India Starts on undefined Get Details Skills you'll gain: Duration: 7 Months S P Jain Institute of Management and Research CERT-SPJIMR Fintech & Blockchain India Starts on undefined Get Details by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Learn The Most Successful Intraday Strategy in Just 2 Hr. thefutureuniversity Learn More Undo Read More...
Time of India
28 minutes ago
- Time of India
Biocon plans to launch generic Wegovy obesity drug in India by 2027, CEO says
Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters, seeking to tap into a market that is estimated to grow to $150 billion globally by the early 2030s. The push comes after Danish drugmaker Novo Nordisk and U.S.-based rival Eli Lilly saw skyrocketing demand for their obesity drugs Wegovy and Zepbound. Explore courses from Top Institutes in Select a Course Category MCA Management Operations Management Design Thinking Cybersecurity Data Analytics Degree Data Science Project Management Product Management Leadership Technology Others Healthcare Digital Marketing CXO others PGDM Public Policy Finance Artificial Intelligence Data Science MBA healthcare Skills you'll gain: Programming Proficiency Data Handling & Analysis Cybersecurity Awareness & Skills Artificial Intelligence & Machine Learning Duration: 24 Months Vellore Institute of Technology VIT Master of Computer Applications Starts on Aug 14, 2024 Get Details Biopharmaceutical company Biocon plans to submit a request for approval to India's drug regulator by the end of 2026 and potentially launch in 2027 through a partner, CEO Siddharth Mittal said in an email interview on Tuesday. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giá vàng đang tăng mạnh trong năm 2025 — Các nhà giao dịch thông minh đã tham gia IC Markets Tìm hiểu thêm Undo The company, which also makes insulin products, expects to complete late-stage trials within the next 12 to 18 months, he added. "Biocon is actively progressing with filings for semaglutide in Canada as well as many other emerging markets," Mittal said. Live Events Semaglutide is the active ingredient in Novo's drugs Ozempic and Wegovy, used for diabetes and weight-loss management. Indian generic drugmakers, including Dr Reddy's and Cipla , have been racing to produce cheaper versions of Wegovy when semaglutide goes off patent in 2026. Novo launched Wegovy in India for diabetes and weight-loss management in June after Lilly's Mounjaro sales doubled within a few months following its launch in the south Asian country. Biocon plans to file with Canadian regulatory authorities this quarter for generic versions of Ozempic and later this year for Wegovy versions. "Subject to approval, we could look at a market launch in late 2026 or early 2027," he said. Canada has not approved any such therapies yet, the company said. In addition to Canada, Biocon will focus on large emerging markets such as Brazil and Mexico in Latin America, Malaysia and Hong Kong, countries in the Middle East, as well as Australia, and New Zealand to launch obesity drugs, according to the CEO. In markets where Biocon does not have a direct presence, it is seeking local partnerships to commercialise its products, Mittal said.
Time of India
28 minutes ago
- Time of India
India's pharma & healthcare sector records transactions worth $1.3 bn in Q2
India's pharma and healthcare sector recorded 57 transactions valued at $1.30 billion in the quarter ended June, including IPO and QIP activity—reflecting a 20% drop in volumes and a 50% decline in values compared to the previous quarter, according to a report from Grant Thornton Bharat . Excluding public market activity, the quarter saw 56 deals worth $788 million, down 16% in volumes and 62% in values. Explore courses from Top Institutes in Select a Course Category Data Science PGDM Data Science CXO MBA Operations Management MCA Digital Marketing Product Management healthcare Artificial Intelligence Management Design Thinking others Cybersecurity Healthcare Leadership Finance Project Management Data Analytics Public Policy Others Technology Degree Skills you'll gain: Duration: 10 Months E&ICT Academy, Indian Institute of Technology Guwahati CERT-IITG Prof Cert in DS & BA with GenAI India Starts on undefined Get Details Skills you'll gain: Duration: 11 Months E&ICT Academy, Indian Institute of Technology Guwahati CERT-IITG Postgraduate Cert in AI and ML India Starts on undefined Get Details Skills you'll gain: Duration: 30 Weeks IIM Kozhikode SEPO - IIMK-AI for Senior Executives India Starts on undefined Get Details Skills you'll gain: Duration: 11 Months IIT Madras CERT-IITM Advanced Cert Prog in AI and ML India Starts on undefined Get Details Skills you'll gain: Duration: 10 Months IIM Kozhikode CERT-IIMK DABS India Starts on undefined Get Details Despite this moderation, the sector remained a key contributor to overall deal activity, accounting for 10% of volumes and 6% of values, according to the report. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Đây có thể là thời điểm tốt nhất để giao dịch vàng trong 5 năm qua IC Markets Tìm hiểu thêm Undo The report captures data for the first quarter till June 26 and hence does not capture the Torrent Pharma and JB Chemicals deal that was announced end of the month. Torrent will acquire 46.39% equity stake (on a fully diluted basis) of JB Chemicals through a share purchase agreement for Rs 11,917 crores at Rs 1,600 per share. The pharma and biotech segment led in terms of value, fuelled by large capital raises such as Biocon 's $523 million QIP and strategic cross-border M&A. Live Events Hospital platforms evolved along two tracks: consolidation by multispecialty giants and regional expansion by focused, single-specialty players. On the consumer front, HealthTech, Diagnostics, and Wellness segments made up nearly half of the deal volume, signalling sustained investor interest in digital platforms, home-based services, and preventive care. 'While deal activity in Q2 2025 moderated, investor confidence in India's pharma and healthcare ecosystem continues— especially in segments demonstrating scalability, innovation, and public market readiness,' said Bhanu Prakash, Partner and Healthcare Services Industry Leader, Grant Thornton. 'Pharma and biotech led in value, powered by capital raises and strategic cross-border moves, while hospitals and healthtech platforms continued to evolve along distinct, high-potential growth paths. As preventive care and digital health gain ground, we expect sharper, more focused bets in the second half of the year,' he said. M&A activity in Q2 remained stable in terms of volume, recording 23 deals, but saw a sharp 86% drop in deal values compared to the previous quarter— largely due to the absence of large platform acquisitions and a non-disclosure of deal values, with 74% of transaction values undisclosed. Domestic deals dominated the landscape, contributing 87% to deal volumes and 83% to overall values. Hospital platform consolidation was the key driver of domestic activity, while the pharma and biotech segments led in value terms. The top M&A deal of the quarter was Emcure Pharmaceuticals Ltd's acquisition of Zuventus Healthcare for $84 million. PE activity in the sector remained active in Q2 2025, recording 33 deals worth $580 million. While deal volumes declined by 21% compared to the previous quarter, values saw a modest 3% uptick—driven by a few mid-sized investments. Notable among these were General Catalyst's $218 million infusion into PB Healthcare and Advent International's $175 million stake in Felix Pharma. These two transactions together contributed significantly to value activity, making Q2 the second-highest quarter by value since Q2 2024. Despite the lower deal count, the segment continued to attract targeted capital, especially in hospital platforms and pharma-focused plays, reflecting investor confidence in scalable, essential healthcare models amid evolving global headwinds. Public market activity in the sector remained subdued in Q2 2025, with no IPOs recorded—marking a sharp contrast to the previous quarter, which saw three listings raise $503 million. However, QIP activity surged during the quarter, led by Biocon's $523 million QIP. This single transaction contributed nearly 40% of the total quarterly sector deal value, highlighting the continued reliance of large, established players on selective capital raises to fund growth and strengthen balance sheets amid a muted broader capital markets environment.
